Last reviewed · How we verify
NCT07051187: WGc0201-HBV
A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection
Phase 1 trial testing WGc0201 in Chronic Hepatitis B Virus (Hbv) in 9 participants. Currently enrolling.
30 July 2026
Quick facts
| Lead sponsor | Jiyan Liu |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 1 April 2026 |
| Primary completion | 30 July 2026 |
| Estimated completion | 30 July 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- WGc0201 — full drug profile →
Conditions studied
- Chronic Hepatitis B Virus (Hbv) — all drugs for Chronic Hepatitis B Virus (Hbv) →
Sponsor
Jiyan Liu — full company profile →
Who can join
Adults 18 to 65, any sex, with Chronic Hepatitis B Virus (Hbv). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Existing nucleoside analogues (NAs) and interferon therapy for chronic hepatitis B (CHB) have limitations, including drug resistance, low HBsAg clearance rates, and irreversible immunosuppression. Therapeutic vaccines, by activating virus-specific T cells and B cells, hold promise for achieving functional cure (HBsAg clearance + sustained HBV DNA negativity). This study is an open-label, single-arm, dose-escalation Phase I clinical trial. The study population consists of patients with chronic hepatitis B virus infection who have achieved virological stability following standard antiviral therapy. Phase I (dose exploration): three dose groups, with three patients per group. The primary objective is to observe and evaluate the safety of the WGc0201 vaccine in the study population (incidence and severity of adverse events).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
mRNA vaccines for HBV: Mechanisms, preclinical advances, and therapeutic clinical progress.
Pechnikova NA, Zafeiriou-Chatziefraimidou M, Poimenidou M, Patsidou C, et al · · 2026 · PMID 41583559 · DOI 10.1016/j.omtn.2025.102819 -
Do the therapeutic vaccines hold hope for the treatment of hepatitis B?
Yan Q, Fu X, Wang Y, Wang G. · · 2025 · PMID 41014398 · DOI 10.1007/s12072-025-10907-2
Verify or expand the search:
- PubMed search for NCT07051187
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Jiyan Liu trials
Trials by the same sponsor.
- NCT07518979 — EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Can · Phase 2 · not yet recruiting
- NCT07054307 — MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinom · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07051187 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiyan Liu
- Last refreshed: 7 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07051187.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing